| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 178 | 198 | 193 | 203 | 205 | 225 | 225 | 210 | 146 | 291 | 279 | 294 | 346 | 308 | 296 | 312 | 283 | 305 | 292 | 284 | 280 | 310 | 293 | 334 | 316 | 353 | 325 | 352 | 394 | 430 |
| Expenses | 132 | 146 | 142 | 145 | 156 | 161 | 159 | 173 | 131 | 198 | 188 | 195 | 224 | 212 | 218 | 231 | 211 | 221 | 215 | 212 | 214 | 234 | 226 | 251 | 235 | 260 | 251 | 283 | 296 | 321 |
| EBITDA | 46 | 53 | 51 | 58 | 49 | 64 | 66 | 37 | 15 | 94 | 90 | 99 | 122 | 96 | 78 | 81 | 72 | 83 | 77 | 72 | 66 | 76 | 67 | 83 | 81 | 93 | 75 | 69 | 97 | 109 |
| Operating Profit % | 25 % | 25 % | 26 % | 28 % | 24 % | 28 % | 29 % | 16 % | 8 % | 32 % | 32 % | 33 % | 31 % | 30 % | 26 % | 24 % | 24 % | 26 % | 25 % | 25 % | 23 % | 24 % | 22 % | 24 % | 25 % | 26 % | 22 % | 18 % | 23 % | 25 % |
| Depreciation | 5 | 5 | 5 | 5 | 8 | 9 | 11 | 11 | 10 | 11 | 11 | 14 | 13 | 15 | 17 | 18 | 21 | 22 | 23 | 23 | 21 | 22 | 25 | 26 | 26 | 27 | 28 | 29 | 31 | 32 |
| Interest | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 6 | 3 | 5 | 6 | 8 | 7 | 6 | 6 | 6 | 6 | 5 | 6 | 5 | 5 | 5 | 5 | 5 | 6 |
| Profit Before Tax | 42 | 48 | 46 | 52 | 39 | 53 | 53 | 23 | 4 | 81 | 78 | 82 | 103 | 78 | 56 | 57 | 43 | 55 | 48 | 42 | 39 | 48 | 37 | 51 | 51 | 61 | 42 | 36 | 61 | 71 |
| Tax | 14 | 18 | 14 | 17 | 12 | 10 | 11 | 8 | 1 | 21 | 19 | 20 | 28 | 19 | 15 | 16 | 9 | 14 | 12 | 8 | 10 | 13 | 10 | 14 | 13 | 15 | 11 | 7 | 16 | 18 |
| Net Profit | 27 | 30 | 31 | 35 | 27 | 43 | 42 | 16 | 3 | 61 | 59 | 61 | 75 | 58 | 41 | 40 | 34 | 41 | 36 | 34 | 29 | 36 | 27 | 37 | 38 | 47 | 32 | 29 | 45 | 53 |
| EPS in ₹ | 4.83 | 6.14 | 6.26 | 6.87 | 5.34 | 8.57 | 8.38 | 3.09 | 0.57 | 11.88 | 11.50 | 12.05 | 14.65 | 11.39 | 8.02 | 7.81 | 6.53 | 7.88 | 6.99 | 6.51 | 5.62 | 6.92 | 5.30 | 7.11 | 7.41 | 9.08 | 6.12 | 5.69 | 8.70 | 10.17 |
Metropolis Healthcare
Metropolis Healthcare
1,932.90
-1.20
(-0.06%)
Market Cap
₹10,013.86 Cr
PE Ratio
63.88
Volume
459.00
Day High - Low
₹1,935.90 - ₹1,928.00
52W High-Low
₹2,263.00 - ₹1,315.00
Key Fundamentals
Market Cap
10,013.86 Cr
EPS
28.29
PB Ratio
7.08
Book Value
276.43
EBITDA
318.10
Dividend Yield
0.00 %
Industry
Healthcare Services Sector
Healthcare Service Provider ROE Growth %
-
Debt to Equity
0.17
Analyst Rating and Forecast
- By Refinitiv from18 analysts
Actual
Company News
View All News
Metropolis Healthcare Limited reported strong quarterly results with group revenue growing 23% year-over-year in Q2 FY26. The company's organic business achieved 12% revenue growth with EBITDA margins improving to 26.8% compared to 26.2% in the previous year, representing a 60 basis points expansion. Patient volumes reached 3.6 million with a 6% growth, while test volumes stood at 7.4 million, also growing 6% year-over-year. The B2C segment contributed 59% of total revenue with 11% growth, while B2B segment recorded 14% growth. TruHealth and Specialty segments grew by 21% and 15% respectively. Core Diagnostics, a recent acquisition, showed margin improvement from breakeven in March to high-single-digit margins. The company added approximately 200 collection centres in the first half and plans to add another 300 in the second half. Management maintained their full-year guidance and confirmed no new acquisitions are planned for the next 6-9 months as they focus on organic growth and integration of recent acquisitions.
Metropolis Healthcare is progressing with the integration of Core Diagnostics, which it acquired for Rs 247 crore in late 2024. The company expects Core Diagnostics to achieve double-digit margins by the end of FY26, improving from breakeven in Q4FY25 to low single-digit margins in Q1FY26 and high single-digit margins in Q2FY26. Managing Director Surendran Chemmenkotil stated that Core Diagnostics' margins should align with Metropolis' overall margins within three years of acquisition. The acquisition was aimed at strengthening the company's cancer diagnostics portfolio and expanding presence in Northern and Eastern India. Metropolis reported strong quarterly results with revenue rising 22.7% to Rs 429 crore, EBITDA up 20.4% to Rs 108 crore, and net profit increasing 13.2% to Rs 52.7 crore. The company's TruHealth segment is showing 20% growth.
Metropolis Healthcare announced during a conference call that the company expects volume growth of 10-11% for the year.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
3,085.00 | #1 25,844.74 | 48.50 | #1 2,554.80 | 11.28 | #1 492 | 16.36 | 47.48 | |
1,000.70 | 10,279.68 | 68.44 | 699.70 | 23.06 | 144 | 2.85 | 47.58 | |
1,932.90 | #3 10,013.86 | #8 63.88 | #2 1,346.30 | #9 10.64 | #2 146 | #7 13.28 | 43.59 | |
498.20 | 7,920.55 | 63.84 | 702.20 | 20.80 | 91 | 81.06 | 56.19 | |
814.75 | 2,642.94 | 31.32 | 742.70 | 16.70 | 78 | 22.45 | 53.18 | |
289.15 | 1,505.92 | 50.33 | 255.90 | 15.11 | 31 | -13.73 | 33.69 | |
1,309.00 | 1,134.16 | 22.86 | 111.60 | 28.72 | 48 | 0.67 | 46.63 | |
326.95 | 1,040.04 | -112.32 | 1,170.80 | -18.47 | -134 | 90.05 | 60.67 | |
576.35 | 946.63 | #1 22.60 | 147.80 | #1 134.60 | 19 | #1 760.87 | 83.79 | |
338.40 | 827.46 | 34.54 | 232.20 | 30.60 | 24 | 187.06 | 59.67 |
Growth Rate
Revenue Growth
10.64 %
Net Income Growth
13.23 %
Cash Flow Change
-0.50 %
ROE
-6.76 %
ROCE
-11.55 %
EBITDA Margin (Avg.)
-1.42 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 530 | 553 | 752 | 1,004 | 1,530 | 1,502 | 1,555 | 1,867 |
| Fixed Assets | 207 | 213 | 296 | 343 | 1,059 | 1,121 | 1,177 | 1,447 |
| Current Assets | 300 | 305 | 397 | 609 | 393 | 303 | 316 | 346 |
| Capital Work in Progress | 0 | 6 | 3 | 0 | 6 | 20 | 0 | 0 |
| Investments | 102 | 33 | 14 | 10 | 16 | 15 | 55 | 71 |
| Other Assets | 221 | 301 | 439 | 651 | 450 | 347 | 323 | 349 |
| Total Liabilities | 530 | 553 | 752 | 1,004 | 1,530 | 1,502 | 1,555 | 1,867 |
| Current Liabilities | 91 | 125 | 170 | 204 | 302 | 265 | 246 | 294 |
| Non Current Liabilities | 11 | 8 | 58 | 92 | 341 | 246 | 210 | 238 |
| Total Equity | 429 | 420 | 525 | 708 | 888 | 991 | 1,099 | 1,335 |
| Reserve & Surplus | 405 | 409 | 513 | 696 | 876 | 978 | 1,086 | 1,313 |
| Share Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 4 | 14 | -1 | 18 | 8 | 56 | 279 | -321 | 3 | -6 | -23 |
| Investing Activities | -56 | 96 | -86 | 1 | 36 | -104 | 63 | -736 | 48 | -89 | -199 |
| Operating Activities | 70 | 91 | 102 | 104 | 90 | 215 | 249 | 253 | 247 | 264 | 263 |
| Financing Activities | -10 | -174 | -17 | -87 | -118 | -55 | -33 | 163 | -292 | -181 | -87 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 50.38 % | 50.37 % | 50.33 % | 49.50 % | 49.79 % | 49.79 % | 49.76 % | 49.76 % | 49.75 % | 49.75 % | 49.74 % | 49.74 % | 49.67 % | 49.62 % | 49.43 % | 49.40 % | 48.90 % | 48.89 % | 48.89 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 24.29 % | 0.00 % | 18.90 % | 18.25 % | 18.56 % | 16.73 % | 15.29 % | 12.83 % | 12.52 % |
| DIIs | 15.34 % | 14.22 % | 11.77 % | 10.63 % | 15.32 % | 13.85 % | 11.88 % | 13.30 % | 13.64 % | 14.47 % | 16.86 % | 20.28 % | 24.86 % | 27.43 % | 28.02 % | 30.00 % | 30.30 % | 32.40 % | 33.10 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 3.95 % | 3.98 % | 4.24 % | 6.50 % | 9.14 % | 9.26 % | 9.45 % | 9.73 % | 8.53 % | 8.15 % | 7.78 % | 6.63 % | 5.24 % | 4.07 % | 3.54 % | 3.34 % | 3.84 % | 4.16 % | 3.69 % |
| Others | 30.33 % | 31.43 % | 33.66 % | 33.37 % | 25.75 % | 27.10 % | 28.91 % | 27.21 % | 28.08 % | 27.62 % | 1.32 % | 23.35 % | 1.33 % | 0.63 % | 0.45 % | 0.53 % | 1.68 % | 1.72 % | 1.80 % |
| No of Share Holders | 30,679 | 33,527 | 43,552 | 64,168 | 79,895 | 86,404 | 90,090 | 91,452 | 84,269 | 89,692 | 86,249 | 79,878 | 68,283 | 58,108 | 51,852 | 48,572 | 49,293 | 50,015 | 47,846 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 13.26 | 8 | 8 | 8 | 8 | 4 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 1.03 | 0.36 | 0.39 | 0.67 | 0.46 | 0.26 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 19 Feb 2021 |  Dividend | ₹ 8.00 /share | 17 Feb 2021 | 2,163.55 | 2,011.85 |
| 22 Feb 2022 | Dividend | ₹ 8.00 /share | 21 Feb 2022 | 2,459.95 | 1,976.10 |
| 23 Feb 2023 | Dividend | ₹ 8.00 /share | 23 Feb 2023 | 1,289.35 | 1,348.60 |
| 17 Nov 2023 | Dividend | ₹ 4.00 /share | 17 Nov 2023 | 1,472.25 | 1,606.85 |
| 21 Aug 2024 |  Annual General Meeting | NA | 21 Aug 2024 | 2,098.30 | 2,091.55 |
| 08 Nov 2024 |  Quarterly Result Announcement | NA | 08 Nov 2024 | 2,119.10 | 2,112.60 |
| 04 Feb 2025 | Quarterly Result Announcement | NA | 04 Feb 2025 | 1,708.90 | 1,757.75 |
| 13 May 2025 | Quarterly Result Announcement | NA | 13 May 2025 | 1,694.80 | 1,712.30 |
| 07 Aug 2025 | Quarterly Result Announcement | NA | 07 Aug 2025 | 2,019.00 | 2,055.70 |
| 13 Aug 2025 | Annual General Meeting | NA | 13 Aug 2025 | 1,938.80 | 2,092.90 |
| 04 Nov 2025 | Quarterly Result Announcement | NA | 04 Nov 2025 | 1,953.20 | 2,004.45 |
| 11 Nov 2025 | Dividend | ₹ 4.00 /share | 11 Nov 2025 | 2,004.45 | 1,936.05 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
3 days ago
3 days agoIntimation Of Cancellation Of Analyst / Institutional Investor Meeting Scheduled On November 21 20256 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 12, 2025
Nov 12, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 11, 2025
Nov 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 06, 2025
Nov 06, 2025Update On Schedule Of Earnings Conference Call For The Quarter And Half Year Ended September 30 2025Nov 05, 2025
Nov 05, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 05, 2025
Nov 05, 2025Announcement under Regulation 30 (LODR)-Investor PresentationNov 04, 2025
Nov 04, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 04, 2025
Nov 04, 2025Corporate Action-Board approves DividendNov 04, 2025
Nov 04, 2025Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30 2025Nov 04, 2025
Nov 04, 2025Board Meeting Outcome for For The Meeting Held Today (November 04 2025)Nov 04, 2025
Nov 04, 2025Grant Of Stock BenefitsNov 04, 2025
Nov 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 28, 2025
Oct 28, 2025Board Meeting Intimation for Considering And Approving The Un-Audited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30 2025 And Declaration Of Interim Dividend If Any For The Financial Year 2025-26Oct 28, 2025
Oct 28, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSOct 13, 2025
Oct 13, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 07, 2025
Oct 07, 2025Business Update For Q2FY26Oct 06, 2025
Oct 06, 2025Closure of Trading WindowSep 30, 2025
Sep 30, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 18, 2025
Sep 18, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionSep 18, 2025
Sep 18, 2025Announcement under Regulation 30 (LODR)-AcquisitionSep 16, 2025
Sep 16, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 10, 2025
Sep 10, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 10, 2025
Sep 10, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 14, 2025
Aug 14, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 14, 2025
Aug 14, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 08, 2025
Aug 08, 2025Update On Schedule Of Earnings Conference Call For The Quarter Ended June 30 2025Aug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-AcquisitionAug 07, 2025
Aug 07, 2025Unaudited Standalone And Consolidated Financial Results For The Quarter Ended June 30 2025Aug 07, 2025
Aug 07, 2025Board Meeting Outcome for The Meeting Held Today (August 07 2025)Aug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 01, 2025
Aug 01, 2025Board Meeting Intimation for Considering And Approving The Un-Audited Standalone And Consolidated Financial Results For The Quarter Ended June 30 2025Jul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 23, 2025
Jul 23, 2025Letter To Shareholders Containing Weblink Of 25Th Annual General Meeting And Annual Report For The Financial Year 2024-25Jul 22, 2025
Jul 22, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 22, 2025
Jul 22, 2025Notice Of 25Th Annual General Meeting For The Financial Year 2024-25Jul 22, 2025
Jul 22, 2025Reg. 34 (1) Annual Report.Jul 22, 2025
Jul 22, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 21, 2025
Jul 21, 2025Disclosure Under Regulation 30 Of Listing RegulationsJul 18, 2025
Jul 18, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 11, 2025
Jul 11, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJul 08, 2025
Jul 08, 2025Business Update For Q1FY26Jul 04, 2025
Jul 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 04, 2025
Jul 04, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jul 02, 2025
Jul 02, 2025Mutual Fund Holdings
Tata Focused Fund Direct - Growth 
UTI Large Cap Fund Direct-Growth 
Bandhan Small Cap Fund Direct-Growth 
NJ ELSS Tax Saver Scheme Direct - Growth 
Franklin India Aggressive Hybrid Fund Direct-Growth 
Baroda BNP Paribas Flexi Cap Fund Direct - Growth 
Samco Special Opportunities Fund Direct - Growth 
ITI Bharat Consumption Fund Direct-Growth 
Kotak Small Cap Fund Direct-Growth 
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth 
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth 
DSP Nifty Smallcap250 Quality 50 Index Fund Direct - Growth 
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth 
HDFC Nifty Smallcap 250 Index Fund Direct-Growth Technical Indicators
RSI(14)
Neutral 43.59
ATR(14)
Less Volatile 43.45
STOCH(9,6)
Neutral 43.47
STOCH RSI(14)
Neutral 32.60
MACD(12,26)
Bearish -0.26
ADX(14)
Weak Trend 12.92
UO(9)
Bearish 48.98
ROC(12)
Downtrend And Accelerating -1.11
WillR(14)
Neutral -73.75
About Metropolis Healthcare
Metropolis Healthcare Limited is an Indian diagnostic services company operating across India and Africa. Founded in 1980 as a pathology partnership, it has evolved into a public company offering a wide range of clinical laboratory tests and profiles. The company operates through a hub and spoke model with 115 clinical laboratories, including a global reference laboratory in Mumbai, regional reference laboratories, satellite laboratories, and express laboratories. Metropolis provides services to both B2B and B2C markets, covering 197 cities in India and has operations in several African countries. The company offers approximately 3,487 clinical laboratory tests and 530 profiles, and has expanded its network through acquisitions and mergers. Metropolis is known for its quality diagnostics and has received awards for customer service and healthcare excellence.
Listing Date
15 Apr, 2019(6 Years,
13 days)
Chairperson NameAmeera Sushil Shah
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
